Proxy Results (Form 8-K)

Effective January 10, 2025, Vincerx Pharma, Inc. (the "Company") terminated the Sales Agreement with Leerink Partners LLC dated March 29, 2024 (the "Sales Agreement"), pursuant to which the Company could offer and sell shares of the Company's common stock having an aggregate offering price of up to $50,000,000 in transactions deemed to be "at-the-market"offerings as defined in Rule 415(a)(4) of the Securities Act of 1933 (the "ATM Offering"), and the ATM Offering for which the Company filed a prospectus supplement and accompanying prospectus dated March 29, 2024 (the "ATM Prospectus"). Prior to the termination of the Sales Agreement and the ATM Offering, the Company sold an aggregate of $2,474,596.53 of its common stock under the Sales Agreement pursuant to the ATM Prospectus.